The Sickle Cell Cure Exists. Why Can’t Patients Get It?
For the 100,000 Americans living with sickle cell disease, a life-changing cure is no longer a distant dream. It exists. Two years ago, the FDA approved two revolutionary gene therapies, Casgevy and Lyfgenia, with an “extremely high” cure rate. [1] Yet for most patients, this miracle remains cruelly out of reach. A combination of staggering […]
FDA Approves First-Ever Treatment for Deadly Stem Cell Transplant Complication
For patients undergoing stem cell transplants, the journey is already fraught with risk. Now, a new FDA approval offers hope against one of the most dangerous and common complications. On December 24, 2025, the FDA approved Yartemlea (narsoplimab), the first and only treatment for hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA). [1] [2] This is […]
New Freezing Method Makes Stem Cells Ready-to-Use
Stem cell therapies hold the promise of curing countless diseases, but their high cost and complex handling have been major roadblocks. A significant part of that challenge is the delicate process of freezing and thawing these powerful cells. Now, a breakthrough from Kobe University in Japan, published just days ago, offers a simple, inexpensive solution […]
Cell Encapsulation: A New Hope for Diabetes Treatment
A Revolutionary Approach to Diabetes Management Millions of people worldwide rely on daily insulin injections to manage their diabetes. Avant Technologies and SGAustria are partnering to change that. Their innovative approach uses cell encapsulation technology to offer a potential long-term solution. This partnership combines Avant’s work in developing cell-based therapies with SGAustria’s clinically proven Cell-in-a-Box® […]
Big Nova’s $3M Gift to NMDP Boosts Blood Stem Cell Transplants
A recent $3 million donation from Big Nova to NMDP is a significant step forward in the fight against blood cancer. This gift helps NMDP’s mission to provide life-saving blood stem cell transplants to more patients. This donation also helped NMDP surpass its $100 million fundraising goal. The campaign, which started in 2020, will help thousands of patients […]
Age-Reversal for Stem Cells: What Mount Sinai’s Lysosome Breakthrough Means
A New Hope for Healthy Aging Scientists at the Icahn School of Medicine at Mount Sinai have made a groundbreaking discovery, reversing the aging process in blood-forming stem cells in mice. This breakthrough, published in Cell Stem Cell, offers new hope for treating age-related blood disorders and potentially even slowing the overall aging process. The key […]
Cellipont and Ronawk Forge Alliance to Revolutionize MSC Expansion for Regenerative Medicine
A landmark strategic collaboration has been announced between CelliPont Bioservices, a leading cell therapy Contract Development and Manufacturing Organization (CDMO), and Ronawk, the innovative developer of the Bio-OS™ biological operating system. This partnership, unveiled on November 19, 2025, is set to tackle some of the most significant hurdles in regenerative medicine by accelerating the scalable, […]
Maryland Announces FY26 Stem Cell Research Funding
Maryland Backs Innovation in Regenerative Medicine The Maryland Stem Cell Research Commission (MSCRC) has announced its second funding cycle for fiscal year 2026 (FY26). [1] This initiative invites researchers and companies to submit proposals that will accelerate stem cell research, its translation into therapies, and commercialization within Maryland. [1] This funding is a key part […]
Pluristyx Announces Two Key Licensing Agreements for iPSC Portfolio
Pluristyx, a biotechnology company, has executed two commercial clinical use licensing agreements. These agreements provide access to Pluristyx’s clinical-grade iPSC lines and gene engineering platform technologies. The goal is to develop next-generation cell therapies. Advancing Neurological and Regenerative Therapies One agreement is with a company developing a treatment for a neurological disease. This partnership will […]
IN8bio Expands Leukemia Clinical Trial, Adds Ohio State University as New Site
IN8bio, a clinical-stage biopharmaceutical company, has expanded its Phase 1 clinical trial for INB-100. The Ohio State University is now a new clinical site for the trial. This expansion aims to accelerate enrollment and completion of the study. INB-100 Clinical Trial The INB-100 trial is evaluating a donor-derived gamma-delta T cell therapy for leukemia patients […]